The significant costs associated with gene-based therapies is pushing care providers and payers to develop new solutions for covering the expenses which can reach $1 million per patient.
Novartis AG’s new cancer therapy rings up a $475,000 price tag, while Gilead Sciences has its rival drug set at $373,000.
But while both CAR-T treatments come in below the $500,000 threshold, administering the treatments can result in hundreds of thousands of dollars being tacked on to the bill, the Wall Street Journal reports.
According to the WSJ article, there’s little information about how much hospitals will be paid for the new therapies.
“It is about systems that don’t work well and aren’t set up for cutting-edge new technologies,” Standford University health system business manager Gary Goldstein said. “And if we don’t get this one right, what about the next one?”